Allegheny Health Network
Find a
Doctor
Request An Appointment Login to
MyChart
Patient
Center
News Classes &
Events
Contact
Us
Call 412.Doctors

Active Clinical Trials

The Johns Hopkins Breast Cancer Program Initiative to Reduce the Discontinuation Rate of Adjuvant Endocrine Therapy through Symptom Monitoring and Management: A Feasibility Study

Active NCT: N/A
Allegheny General Hospital
Allegheny General Hospital

Category:
Cancer - Breast
Sponsor: 
Johns Hopkins Medicine and AHN Cancer Fund
Contact: 

For more information about this trial, please call 412-330-6151 or send an email to ClinicalTrials@ahn.org.

The Johns Hopkins Breast Cancer Program Initiative to Reduce the Discontinuation Rate of Adjuvant Endocrine Therapy through Symptom Monitoring and Management: A Feasibility Study

Purpose: 

The purpose of the study is to monitor the symptoms that breast cancer patients may experience while receiving endocrine therapy. 

Inclusion Criteria:

  • ≥ 18 years or older
  • Have a smart phone
  • Able to read and understand English
  • Female
  • Stage 0-III hormone receptor positive breast carcinoma (Note: patients with ductal carcinoma in situ and/or invasive breast cancer are eligible).
    • Hormone receptor positivity defined as estrogen receptor and/or progesterone receptor ≥ 1%.
  • Provider plans to initiate adjuvant ET with tamoxifen or an aromatase inhibitor with or without ovarian suppression
    • Patients who have previously used another ET and who are switching to a new ET are eligible.
    • Patients may also be eligible if they are concurrently receiving radiation therapy and/or anti-HER2 targeted therapy.

Exclusion Criteria

  • Metastatic breast cancer
  • Lobular Carcinoma in Situ (LCIS) alone (i.e. without DCIS and/or invasive carcinoma of the breast)
  • Currently receiving chemotherapy
  • Patients initiating ET for chemoprevention for high risk non-malignant breast disease are not eligible